SCHEMBL1819151

SCHEMBL1819151

CONC(=O)C(C)(Oc1cccnc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.41
GPR132 Q9UNW8 1/20 0.40
CYP3A4 P08684 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 4/20 0.39
MAPK1 P28482 2/20 0.39
MEN1 O00255 2/20 0.39
GAA P10253 2/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
RAB9A P51151 2/20 0.38
NOTUM Q6P988 1/20 0.38
KDM4C Q9H3R0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1818707 0.86 PPARA (0.47) CYP2C19KMT2AALDH1A1MEN1HTT
SCHEMBL1823231 0.86 CNR1 (0.42) CNR1GPR132CYP3A4CYP1A2CYP2C9
SCHEMBL1817637 0.82 KMT2A (0.43) CNR1GPR132CYP3A4CYP1A2CYP2C9
SCHEMBL1821690 0.81 PPARG (0.46) KMT2AALDH1A1MEN1LMNARAB9A
SCHEMBL1820277 0.80 PPARG (0.47) KMT2AALDH1A1MAPK1MEN1GAA
SCHEMBL1819391 0.79 NPC1 (0.43) KMT2AMAPK1MEN1HTTLMNA
SCHEMBL1819286 0.79 PPARG (0.46) KMT2AALDH1A1MAPK1MEN1HTT
SCHEMBL1824421 0.75 BCHE (0.47) KMT2AALDH1A1MEN1GAAKDM4E
SCHEMBL1821618 0.75 PPARA (0.44) CYP2C19KMT2AALDH1A1MEN1HTT
SCHEMBL1820711 0.72 MCL1 (0.43) KMT2AALDH1A1MEN1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 CNR1 3152/4885GPR132 304/4885CYP3A4 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.